Equity and Equity Compensation Plans (Tables)

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Reserved Shares of Common Stock

We have reserved shares of common stock for future issuance under our 2017 EIP as follows:

	March 31, 2024	December 31, 2023
Stock options issued and outstanding	2,372,110	2,406,453
Restricted stock units outstanding	13,456,113	15,947,173
Shares available for future equity grants	14,333,627	7,991,532
Total shares reserved for future issuance	30,161,850	26,345,158

We have reserved shares of common stock for future issuance under our ESPP as follows:

	Three Months Ended March 31, 2024	Year Ended December 31, 2023
Shares available for issuance at beginning of period	4,378,042	4,695,361
Shares issued during the period	—	(1,491,040)
Total shares available for future issuance at end of period	4,378,042	3,204,321

Schedule of Stock Option Activity

Option activity for the three months ended March 31, 2024 was as follows:

	Number of Options	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding as of January 1, 2024	2,406,453	$	11.14	2.63	$	3,355
Options exercised	(15,333)	6.12
Options expired	(19,010)	8.61
Outstanding as of March 31, 2024	2,372,110	11.19		2.41	13,343
Options exercisable as of March 31, 2024	2,372,110	11.19		2.41	13,343

Schedule of Nonvested Restricted Stock Units Activity

Restricted stock unit activity for the three months ended March 31, 2024 was as follows:

	Restricted Stock Units	Weighted-Average Grant-Date Fair Value
Outstanding as of January 1, 2024	15,947,173	$	9.64
Granted	595,740	7.00
Vested	(2,099,383)	9.13
Forfeited or canceled	(987,417)	13.04
Outstanding or deferred as of March 31, 2024(1)	13,456,113	9.35

(1) Starting with the restricted stock units granted to them in June 2019, our non-employee directors have the option to defer the issuance of common stock receivable upon vesting of such restricted stock units until 60 days following the day they are no longer providing services to us or, if earlier, upon a change in control transaction. The amount reported as vested excludes restricted stock units that have vested but whose settlement into shares has been deferred. The amount reported as outstanding or deferred as of March 31, 2024 includes these restricted stock units. As no further conditions exist to prevent the issuance of the shares of common stock underlying these restricted stock units, the shares are included in basic and diluted weighted shares outstanding used to calculate net loss per share attributable to common stock. The amount of shares whose issuance have been deferred is not considered material and is not reported separately from stock-based compensation in our consolidated statements of changes in mezzanine equity and stockholders’ (deficit) equity.

Schedule of Allocation of Share-based Compensation Costs

Stock-based compensation expense associated with the PSUs was as follows:

	Three Months Ended March 31,
	2024		2023
PSU expense	$	773	$	1,844
Reassessment of achievement of performance conditions	(401)		—
Total expense	$	372	$	1,844

Stock-based compensation, net of forfeitures and the amount capitalized in website and software development costs were as follows:

	Three Months Ended March 31,
	2024		2023
Cost of revenue	$	2,739	$	4,135
Technology and development(1)	8,239		8,127
Marketing	1,431		1,245
General and administrative	5,000		5,318
Stock-based compensation from continuing operations	17,409		18,825
Stock-based compensation from discontinued operations(1)	—		203
Total stock-based compensation	$	17,409	$	19,028

(1) Net of $1,265 and $1,134 of stock-based compensation that was capitalized in the three months ended March 31, 2024 and 2023, respectively.